Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Usman Siddiqui

Neurology Lawrenceburg, IN Medical Doctor

NPI 1114927712 CMS profile 95773

606 Wilson Creek Rd, Ste. 210, Lawrenceburg, IN 47025

Open in the dashboard

General payments

$11,341

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Usman Siddiqui of Lawrenceburg, IN is reported in the CMS Open Payments database as having received $11,341 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142 2
2024 General $525 1
2023 General $8,758 24
2022 General $367 5
2021 General $938 13
2020 General $34 2
2019 General $577 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Usman Siddiqui
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Usman Siddiqui were reported at $142. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Usman Siddiqui Neurology median Middle half National median
2019 $577 $474 $118–$2,177 $163
2020 $34 $367 $82–$2,309 $114
2021 $938 $438 $104–$2,547 $132
2022 $367 $442 $103–$2,388 $149
2023 $8,758 $464 $119–$2,312 $160
2024 $525 $468 $119–$2,323 $164
2025 $142 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $8,672 11 payments
  2. Biogen, Inc. $401 4 payments
  3. AbbVie, Inc. $316 6 payments
  4. ACADIA Pharmaceuticals Inc $297 7 payments
  5. Alexion Pharmaceuticals, Inc. $236 2 payments
  6. Sunovion Pharmaceuticals Inc. $204 25 payments
  7. Amgen Inc. $200 2 payments
  8. Greenwich Biosciences, Inc. $142 3 payments
  9. Horizon Therapeutics plc $124 1 payment
  10. SK Life Science, Inc. $122 1 payment
  11. Other $627 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,366 2 payments
  2. Food and Beverage $2,710 60 payments
  3. Travel and Lodging $2,207 7 payments
  4. Education $59 8 payments
Products named General payments · program years 2019–2025
  1. AMPLATZER AMULET $8,672 11 payments
  2. UBRELVY $316 6 payments
  3. NUPLAZID $297 7 payments
  4. APTIOM $254 29 payments
  5. VUMERITY $192 2 payments
  6. Epidiolex $142 3 payments
  7. UPLIZNA $124 1 payment
  8. XCOPRI $122 1 payment
  9. NURTEC ODT $120 1 payment
  10. Repatha $115 1 payment
  11. Other $524 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

779

Median for Psychiatry & Neurology: 100

Drug cost

$10,664

Median for Psychiatry & Neurology: $2,986

Branded share of claims

16.3%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Divalproex Sodium Er Divalproex Sodium Brand 16 $1,500
Gabapentin Generic 101 $1,308
Ropinirole Hcl Generic 79 $820
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $718
Levetiracetam Generic 20 $674
Topiramate Generic 50 $557
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 19 $490
Tizanidine Hcl Generic 29 $463
Pregabalin Generic 12 $434
Doxepin Hcl Generic 12 $408

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record